Synopsis Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. The objective of this phase 3 trial was to compare nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. This week’s “MED FACT” discusses a clinical trial from The New England Journal of Medicine, “Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma”. Authors: Robert J. Motzer, et.al.
Key Takeaways: The survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib. Objective: The objective of this phase 3 trial was to compare nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. Study Type: Randomized, Phase 3 Participants: 1096 What Was The Need For This Study? Nivolumab plus…
